 |
Ability Pharmaceuticals |
ABTL0815 |
Biodrugs/ Drugs |
Cancer |
Solid Tumors |
1NRP |
|
ABTL0815
Therapeutic area:
Cancer
|
|
Ability Pharmaceuticals |
ABTL1014 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Leukaemia and Lymphomas |
2RP |
|
ABTL1014
Therapeutic area:
Blood and Lymphatic systems
Cancer
|
|
Ability Pharmaceuticals |
ABTL0812 |
Biodrugs/ Drugs |
Cancer |
Lung, Endometrial and Pancreatic Cancer |
4PhII |
|
ABTL0812
Therapeutic area:
Cancer
|
 |
Almirall |
ADP31415 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Pemphigus Vulgaris |
3PhI |
|
ADP31415
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
|
Almirall |
ADP13612 |
Biodrugs/ Drugs |
Dermatology |
Rosacea |
2RP |
|
ADP13612
Therapeutic area:
Dermatology
|
|
Almirall |
LAS41010 |
Biodrugs/ Drugs |
Dermatology |
Atopic Dermatitis |
6Reg. |
|
LAS41010
Therapeutic area:
Dermatology
|
|
Almirall |
TIldrakizumab |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Psoriasis |
6Reg. |
|
TIldrakizumab
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
|
Almirall |
ADP18998 |
Biodrugs/ Drugs |
Dermatology |
Actinic Keratosis |
6Reg. |
|
ADP18998
Therapeutic area:
Dermatology
|
|
Almirall |
P3058 |
Biodrugs/ Drugs |
Dermatology |
Onychomycosis |
5PhIII |
|
P3058
Therapeutic area:
Dermatology
|
|
Almirall |
P3070 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Nail Psoriasis |
5PhIII |
|
P3070
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
|
Almirall |
P3074 |
Biodrugs/ Drugs |
Dermatology |
Androgenetic Alopecia |
5PhIII |
|
P3074
Therapeutic area:
Dermatology
|
|
Almirall |
PAT001 |
Biodrugs/ Drugs |
Dermatology
Genetic Diseases and Dysmorphic syndromes |
Ichthyosis |
4PhII |
|
PAT001
Therapeutic area:
Dermatology
Genetic Diseases and Dysmorphic syndromes
|
|
Almirall |
LAS 41008 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Psoriasis |
6Reg. |
|
LAS 41008
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
 |
Aptatargets |
ApTOLL |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Central Nervous System |
Acute ischemic stroke
Acute coronary syndrome
Atherosclerosis |
2RP |
|
ApTOLL
Therapeutic area:
Cardiovascular and circulatory systems
Central Nervous System
|
 |
APTUS Biotech |
ApTLR-4FT |
Biodrugs/ Drugs |
Central Nervous System |
Acute stroke |
1NRP |
|
ApTLR-4FT
Therapeutic area:
Central Nervous System
|
 |
Araclon Biotech |
ABvac40 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's Disease |
4PhII |
|
ABvac40
Therapeutic area:
Central Nervous System
|
 |
Archivel Farma |
RUTI® |
Vaccines |
Infections |
Active tuberculosis - Latent Tuberculosis |
4PhII |
Europe and South Africa |
RUTI®
Therapeutic area:
Infections
|
 |
ATRYS HEALTH |
NILO1 |
Biodrugs/ Drugs |
Cancer
Central Nervous System |
Brain tumor and brain lesions |
1NRP |
Spain |
NILO1
Therapeutic area:
Cancer
Central Nervous System
|
 |
Bioibérica |
BIS014 |
Biodrugs/ Drugs |
Analgesia & Pain
Central Nervous System |
Neuropathic pain |
2RP |
Europe |
BIS014
Therapeutic area:
Analgesia & Pain
Central Nervous System
|
 |
Bionanoplus |
Psorio-Plus spray and gel |
Biodrugs/ Drugs |
Dermatology |
Help improving and soothing the manifestations of hyperkeratinized skins |
2RP |
|
Psorio-Plus spray and gel
Therapeutic area:
Dermatology
|
|
Bionanoplus |
Amorolfine Transungual Formulation |
Biodrugs/ Drugs |
Infections |
Onychomycosis |
1NRP |
|
Amorolfine Transungual Formulation
Therapeutic area:
Infections
|
|
Bionanoplus |
Ciclopirox Transungual Formulation |
Biodrugs/ Drugs |
Infections |
Onychomycosis |
1NRP |
|
Ciclopirox Transungual Formulation
Therapeutic area:
Infections
|
|
Bionanoplus |
CAX-LAST (Carbenoxolone mucoadhesive paste) |
Biodrugs/ Drugs |
Others |
Carbenoxolone paste for treatment of recurrent aphtous ulcers (RAS) (local mucosal delivery). |
1NRP |
|
CAX-LAST (Carbenoxolone mucoadhesive paste)
Therapeutic area:
Others
|
|
Bionanoplus |
Propylene Glycol Free Minoxidil Topical Formulation |
Biodrugs/ Drugs |
Dermatology |
Hair Loss |
6Reg. |
Europe |
Propylene Glycol Free Minoxidil Topical Formulation
Therapeutic area:
Dermatology
|
|
Bionanoplus |
Cyclosporine Topical Ophthalmic Formulation |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Dry eye Syndrome |
1NRP |
|
Cyclosporine Topical Ophthalmic Formulation
Therapeutic area:
Ophthalmology and optometry
|
|
Bionanoplus |
MUCOZOL-LAST (Miconazole mucoadhesive paste) |
Biodrugs/ Drugs |
Others |
Anti-fungal Miconazole paste for buccal and oral delivery. |
1NRP |
|
MUCOZOL-LAST (Miconazole mucoadhesive paste)
Therapeutic area:
Others
|
 |
Bionaturis |
BNT-014 |
Vaccines |
Infections |
Universal vaccine against common cold (rhinovirus) |
1NRP |
|
BNT-014
Therapeutic area:
Infections
|
|
Bionaturis |
BNT-001 |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
Lysosomal storage diseases: Gaucher's disease. |
1NRP |
|
BNT-001
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
 |
Bioncotech Therapeutics |
BO-110 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
2RP |
Europe |
BO-110
Therapeutic area:
Cancer
|
 |
Bionure |
BN201 |
Biodrugs/ Drugs |
Central Nervous System
Ophthalmology and optometry |
Acute Optic Neuritis, Neuromyelitis Optica, Multiple Sclerosis |
3PhI |
|
BN201
Therapeutic area:
Central Nervous System
Ophthalmology and optometry
|
 |
DIOMUNE SL |
IV1303 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Infections |
Sepsis treatment, Stroke, Rare diseases (CDH), Leishmania, ZIKV |
2RP |
|
IV1303
Therapeutic area:
Autoimmune & Inflammation
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Infections
|
 |
ENTRECHEM |
EC-70124 po for prostate cancer |
Biodrugs/ Drugs |
Cancer |
Castration resistant prostate cancer |
2RP |
|
EC-70124 po for prostate cancer
Therapeutic area:
Cancer
|
|
ENTRECHEM |
Brasilicardin analogs |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Immunosupression |
1NRP |
|
Brasilicardin analogs
Therapeutic area:
Autoimmune & Inflammation
|
|
ENTRECHEM |
EC-8042 iv for liposarcoma |
Biodrugs/ Drugs |
Cancer |
liposarcoma myxoide |
2RP |
|
EC-8042 iv for liposarcoma
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-70124 po for AML |
Biodrugs/ Drugs |
Cancer |
Acute myeloid leukemia |
2RP |
|
EC-70124 po for AML
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-8042 iv for Ewing sarcoma |
Biodrugs/ Drugs |
Cancer |
Solid tumours |
2RP |
|
EC-8042 iv for Ewing sarcoma
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-8042 iv for Triple negative breast cancer |
Biodrugs/ Drugs |
Cancer |
Triple negative breast cancer |
2RP |
|
EC-8042 iv for Triple negative breast cancer
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-70124 po for TNBC |
Biodrugs/ Drugs |
Cancer |
Triple negative breast cancer |
2RP |
|
EC-70124 po for TNBC
Therapeutic area:
Cancer
|
 |
ESTEVE |
EGT-101 |
Gene / Cell Therapy |
Genetic Diseases and Dysmorphic syndromes |
Sanfilippo A syndrome:Lysosomal storage rare disease |
2RP |
|
EGT-101
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
ESTEVE |
E-52862 |
Biodrugs/ Drugs |
Analgesia & Pain |
Neuropathic Pain |
4PhII |
|
E-52862
Therapeutic area:
Analgesia & Pain
|
|
ESTEVE |
E-58425 |
Biodrugs/ Drugs |
Analgesia & Pain |
Acute and chronic, moderate to severe pain |
4PhII |
|
E-58425
Therapeutic area:
Analgesia & Pain
|
|
ESTEVE |
HIVACAT |
Biodrugs/ Drugs |
Infections |
Prophylactic- Therapeutic HIV vaccine |
3PhI |
|
HIVACAT
Therapeutic area:
Infections
|
|
ESTEVE |
EGT-301 |
Gene / Cell Therapy |
Genetic Diseases and Dysmorphic syndromes |
Hunter syndrome: Lysosomal storage disease |
1NRP |
|
EGT-301
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
ESTEVE |
MUMO1 |
Biodrugs/ Drugs |
Analgesia & Pain |
Acute and chronic, moderate to severe pain |
2RP |
|
MUMO1
Therapeutic area:
Analgesia & Pain
|
|
ESTEVE |
EGT-201 |
Gene / Cell Therapy |
Genetic Diseases and Dysmorphic syndromes |
Sanfilippo B syndrome: Lisosomal storage rare disease |
1NRP |
|
EGT-201
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
 |
FECYT |
Pylori |
Biodrugs/ Drugs |
Infections |
H. pylori |
2RP |
|
Pylori
Therapeutic area:
Infections
|
|
FECYT |
p300 |
Biodrugs/ Drugs |
Cancer |
Cancer |
2RP |
|
p300
Therapeutic area:
Cancer
|
|
FECYT |
p38 |
Biodrugs/ Drugs |
Analgesia & Pain
Central Nervous System |
Neuropathic Pain |
2RP |
|
p38
Therapeutic area:
Analgesia & Pain
Central Nervous System
|
 |
FERRER |
Ozenoxacin |
Biodrugs/ Drugs |
Dermatology
Infections |
Dermal infections |
6Reg. |
|
Ozenoxacin
Therapeutic area:
Dermatology
Infections
|
|
FERRER |
FAB-120 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Diabetic Retinopathy |
2RP |
|
FAB-120
Therapeutic area:
Ophthalmology and optometry
|
|
FERRER |
Lorediplon |
Biodrugs/ Drugs |
Central Nervous System |
Sleep disorders |
4PhII |
|
Lorediplon
Therapeutic area:
Central Nervous System
|
|
FERRER |
FAB-117 |
Gene / Cell Therapy |
Central Nervous System |
Spinal Cord Injury |
3PhI |
|
FAB-117
Therapeutic area:
Central Nervous System
|
|
FERRER |
FAB-112 |
Gene / Cell Therapy |
Ophthalmology and optometry |
Corneal Diseases |
2RP |
|
FAB-112
Therapeutic area:
Ophthalmology and optometry
|
 |
FIBROSTATIN |
FSSME12 |
Biodrugs/ Drugs |
Cancer |
Lung and Breast Cancer |
2RP |
Europe |
FSSME12
Therapeutic area:
Cancer
|
|
FIBROSTATIN |
FSMAB26 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Kidney and Genitourinary system |
Lupus nephritis |
1NRP |
Europe |
FSMAB26
Therapeutic area:
Autoimmune & Inflammation
Kidney and Genitourinary system
|
 |
FUND. PROGRESO Y SALUD / IATA (SAS) |
FIBAO-13007 |
Gene / Cell Therapy |
Cancer |
Cancer cells |
2RP |
Europe |
FIBAO-13007
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD / IATA (SAS) |
Engineered Corneas |
Gene / Cell Therapy |
Ophthalmology and optometry |
Corneal ulcers |
4PhII |
Europe |
Engineered Corneas
Therapeutic area:
Ophthalmology and optometry
|
|
FUND. PROGRESO Y SALUD / IATA (SAS) |
Autologous Bone Marrow Mononuclear cells |
Gene / Cell Therapy |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Critical Limb Ischemia in diabetic patients |
3PhI |
Worldwide |
Autologous Bone Marrow Mononuclear cells
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD / IATA (SAS) |
Autologous Bone Marrow progenitors, Adipose and Bone Marrow Mesenchymal stem cells |
Gene / Cell Therapy |
Autoimmune & Inflammation
Central Nervous System |
Stroke, Multiple Sclerosis and ALS |
4PhII |
Europe |
Autologous Bone Marrow progenitors, Adipose and Bone Marrow Mesenchymal stem cells
Therapeutic area:
Autoimmune & Inflammation
Central Nervous System
|
|
FUND. PROGRESO Y SALUD / IATA (SAS) |
Autologous Bone Marrow Mononuclear cells and Adipose Mesenchymal stem cells |
Gene / Cell Therapy |
Digestive System |
Extended Liver resection, Faecal Incontinence |
4PhII |
Europe |
Autologous Bone Marrow Mononuclear cells and Adipose Mesenchymal stem cells
Therapeutic area:
Digestive System
|
|
FUND. PROGRESO Y SALUD / IATA (SAS) |
Autologous Bone Marrow Mononuclear cells |
Gene / Cell Therapy |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Acute Myocardial Infarction/Dilated Myocardiopathy/Chronic Ischemic Cardiopathy/Critical Limb Ischemia in diabetic & non patients |
4PhII |
Europe |
Autologous Bone Marrow Mononuclear cells
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD / IATA (SAS) |
Allogeneic Adipose Mesenchymal stem cells / Allodepleted Bone Marrow Progenitors |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Blood and Lymphatic systems |
Chronic Graft versus Host Disease, Haematological Malignancies |
4PhII |
Europe |
Allogeneic Adipose Mesenchymal stem cells / Allodepleted Bone Marrow Progenitors
Therapeutic area:
Autoimmune & Inflammation
Blood and Lymphatic systems
|
 |
FUND. PROGRESO Y SALUD / OTT (SAS) |
FIBAO-116 |
Biodrugs/ Drugs |
Analgesia & Pain |
Fibromyalgia |
3PhI |
|
FIBAO-116
Therapeutic area:
Analgesia & Pain
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FIMABIS-99 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Nanoemulsions for the treatment of obesity |
2RP |
|
FIMABIS-99
Therapeutic area:
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FIMABIS-13001 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Treatment and/or Prevention of Non-alcoholic fatty liver disease (NAFLD) |
2RP |
|
FIMABIS-13001
Therapeutic area:
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FIMABIS-77 |
Biodrugs/ Drugs |
Central Nervous System |
Hydroxytyrosol ethers |
2RP |
|
FIMABIS-77
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FIMABIS-13007 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Treatment and/or prevention of metabolic and cardiovascular diseases |
2RP |
|
FIMABIS-13007
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FIMABIS-13007 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Treatment and/or Prevention of cardiovascular and metabolic diseases |
2RP |
|
FIMABIS-13007
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FISEVI-14012 |
Biodrugs/ Drugs |
Infections |
Multirresistant infections |
2RP |
Europe |
FISEVI-14012
Therapeutic area:
Infections
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FISEVI-13007 |
Gene / Cell Therapy |
Cancer |
Hepatocarcinoma |
2RP |
Europe |
FISEVI-13007
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FIMABIS-14003 |
Biodrugs/ Drugs |
Dermatology
Infections |
Treatment of mucocutaneous herpes infections |
4PhII |
Europe |
FIMABIS-14003
Therapeutic area:
Dermatology
Infections
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FRM-5 |
Gene / Cell Therapy |
Others |
Transplant |
2RP |
Europe |
FRM-5
Therapeutic area:
Others
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
CABIMER-14001 Condon plasma factors for skin regeneration |
Gene / Cell Therapy |
Autoimmune & Inflammation
Dermatology |
Dermatitis |
1NRP |
Worldwide |
CABIMER-14001 Condon plasma factors for skin regeneration
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FISEVI-13020 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2RP |
Europe |
FISEVI-13020
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
CABIMER-11 New target gene and delivery systems for the Treatment of Retinitis Pigmentosa |
Gene / Cell Therapy |
Ophthalmology and optometry |
Retinitis pigmentosa |
1NRP |
Worldwide |
CABIMER-11 New target gene and delivery systems for the Treatment of Retinitis Pigmentosa
Therapeutic area:
Ophthalmology and optometry
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FISEVI 141 |
Biodrugs/ Drugs |
Infections |
Sepsis, Acute lung injury |
2RP |
Europe |
FISEVI 141
Therapeutic area:
Infections
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
CABIMER-13003 |
Vaccines |
Central Nervous System |
Parkinson |
1NRP |
Worldwide |
CABIMER-13003
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FISEVI-13002 |
Biodrugs/ Drugs |
Cancer |
Multiple myeloma |
2RP |
Europe |
FISEVI-13002
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FIBICO-14003 |
Gene / Cell Therapy |
Musculoskeletal Disorders |
Musculoskeletal disorders |
1NRP |
|
FIBICO-14003
Therapeutic area:
Musculoskeletal Disorders
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FIBAO-91 Melatonine Solution |
Biodrugs/ Drugs |
Infections |
Sepsis |
4PhII |
|
FIBAO-91 Melatonine Solution
Therapeutic area:
Infections
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FISEVI-121 |
Gene / Cell Therapy |
Autoimmune & Inflammation |
Transplant |
2RP |
Europe |
FISEVI-121
Therapeutic area:
Autoimmune & Inflammation
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FIBICO-14002 |
Biodrugs/ Drugs |
Cancer |
Metastatic processes and resistant cancers |
1NRP |
|
FIBICO-14002
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD / OTT (SAS) |
FIBAO-13014 Combination of Ketamine and Meperidine |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Autoimmune & Inflammation |
Mucositis |
3PhI |
|
FIBAO-13014 Combination of Ketamine and Meperidine
Therapeutic area:
Autoimmune & Inflammation
Autoimmune & Inflammation
|
 |
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
New generation of peptides |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Blood and Lymphatic systems
Cardiovascular and circulatory systems
Kidney and Genitourinary system
Metabolic / Endocrinology
Ophthalmology and optometry |
Chronic complications of Diabetes |
2RP |
|
New generation of peptides
Therapeutic area:
Autoimmune & Inflammation
Blood and Lymphatic systems
Cardiovascular and circulatory systems
Kidney and Genitourinary system
Metabolic / Endocrinology
Ophthalmology and optometry
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Peptide derived from a natural compound |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Metabolic / Endocrinology |
Osteoporosis treatment |
1NRP |
|
Peptide derived from a natural compound
Therapeutic area:
Autoimmune & Inflammation
Metabolic / Endocrinology
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Mutli-target siRNA approach |
Gene / Cell Therapy |
Autoimmune & Inflammation
Kidney and Genitourinary system |
Chronic Kidney Disease (CKD)/ Akute Kidney Injury (AKI) |
2RP |
|
Mutli-target siRNA approach
Therapeutic area:
Autoimmune & Inflammation
Kidney and Genitourinary system
|
 |
Fundacion MEDINA |
MDN-0109, MDN-110, MDN-111, MDN- 112 |
Biodrugs/ Drugs |
Infections |
Malaria |
1NRP |
|
MDN-0109, MDN-110, MDN-111, MDN- 112
Therapeutic area:
Infections
|
|
Fundacion MEDINA |
MDN-0090 |
Biodrugs/ Drugs |
Cancer |
Pancreatic Cancer |
1NRP |
|
MDN-0090
Therapeutic area:
Cancer
|
|
Fundacion MEDINA |
MDN-005 |
Biodrugs/ Drugs |
Central Nervous System
Musculoskeletal Disorders |
Amyotrophic lateral sclerosis (ALS) |
1NRP |
|
MDN-005
Therapeutic area:
Central Nervous System
Musculoskeletal Disorders
|
|
Fundacion MEDINA |
MDN-088 |
Biodrugs/ Drugs |
Cancer |
Breast, Colon & Lung Cancer |
1NRP |
|
MDN-088
Therapeutic area:
Cancer
|
|
Fundacion MEDINA |
MDN-018 |
Biodrugs/ Drugs |
Infections |
Fungal Infections |
1NRP |
|
MDN-018
Therapeutic area:
Infections
|
|
Fundacion MEDINA |
MDN-057/MDN-058/MDN-059 |
Biodrugs/ Drugs |
Infections |
Gram negative infections |
1NRP |
|
MDN-057/MDN-058/MDN-059
Therapeutic area:
Infections
|
|
Fundacion MEDINA |
MDN-0145; MDN-0146 |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson |
1NRP |
|
MDN-0145; MDN-0146
Therapeutic area:
Central Nervous System
|
|
Fundacion MEDINA |
MDN-0147; MDN-0148 & MDN-0149 |
Biodrugs/ Drugs |
Cancer |
Melanoma |
1NRP |
|
MDN-0147; MDN-0148 & MDN-0149
Therapeutic area:
Cancer
|
 |
Genmedica Therapeutics |
GMC-252 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Type 2 Diabetes |
3PhI |
Europe |
GMC-252
Therapeutic area:
Metabolic / Endocrinology
|
 |
GP-PHARM |
Triptorelina Depot 1-3 |
Biodrugs/ Drugs |
Cancer |
Prostate Cancer |
3PhI |
Europe and Latinamerica |
Triptorelina Depot 1-3
Therapeutic area:
Cancer
|
|
GP-PHARM |
Risperidona Depot |
Biodrugs/ Drugs |
Central Nervous System |
Schizophrenia |
2RP |
Worldwide |
Risperidona Depot
Therapeutic area:
Central Nervous System
|
|
GP-PHARM |
Octeotride MAR |
Biodrugs/ Drugs |
Cancer
Digestive System |
Acute diarrhoea post chemotherapy |
3PhI |
Worldwide |
Octeotride MAR
Therapeutic area:
Cancer
Digestive System
|
|
GP-PHARM |
Lutrate Depot 45 mg |
Biodrugs/ Drugs |
Cancer |
Prostate Cancer |
3PhI |
Worldwide |
Lutrate Depot 45 mg
Therapeutic area:
Cancer
|
|
GP-PHARM |
Octeotride LAR |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Acromegaly |
4PhII |
Worldwide |
Octeotride LAR
Therapeutic area:
Metabolic / Endocrinology
|
|
GP-PHARM |
Lutrate Depot 22,5 mg |
Biodrugs/ Drugs |
Cancer |
Prostate Cancer |
6Reg. |
|
Lutrate Depot 22,5 mg
Therapeutic area:
Cancer
|
|
GP-PHARM |
Pegylated Liposomes for Oncology |
Biodrugs/ Drugs |
Cancer |
Advanced Ovarian Cancer, Advanced Breast Cancer |
3PhI |
Worldwide |
Pegylated Liposomes for Oncology
Therapeutic area:
Cancer
|
|
GP-PHARM |
TERIPERATIDE |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Osteoporosis |
3PhI |
|
TERIPERATIDE
Therapeutic area:
Musculoskeletal Disorders
|
|
GP-PHARM |
Desmopresina Solution |
Biodrugs/ Drugs |
Kidney and Genitourinary system |
Nocturnal Enuresis |
6Reg. |
|
Desmopresina Solution
Therapeutic area:
Kidney and Genitourinary system
|
|
GP-PHARM |
depot form. |
Biodrugs/ Drugs |
Cancer |
Several |
3PhI |
|
depot form.
Therapeutic area:
Cancer
|
 |
Histocell |
HR004 |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Bone Regeneration |
4PhII |
|
HR004
Therapeutic area:
Musculoskeletal Disorders
|
|
Histocell |
HR016 |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Acute Lung Injury |
2RP |
|
HR016
Therapeutic area:
Respiratory and Pulmonary system
|
|
Histocell |
HC016 |
Biodrugs/ Drugs |
Central Nervous System |
Acute Spinal Cord Injury |
4PhII |
|
HC016
Therapeutic area:
Central Nervous System
|
 |
InKemia IUCT group |
IUCT-DS-0423 |
Biodrugs/ Drugs |
Cancer |
Prostate cancer |
1NRP |
|
IUCT-DS-0423
Therapeutic area:
Cancer
|
|
InKemia IUCT group |
DIS-COM-TROP |
Biodrugs/ Drugs |
Central Nervous System |
Migraine |
1NRP |
|
DIS-COM-TROP
Therapeutic area:
Central Nervous System
|
|
InKemia IUCT group |
IUCT-DS-0347 |
Biodrugs/ Drugs |
Cancer |
Prostate cancer |
1NRP |
Europe |
IUCT-DS-0347
Therapeutic area:
Cancer
|
|
InKemia IUCT group |
DIS-COM-BRA |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Asthma |
1NRP |
|
DIS-COM-BRA
Therapeutic area:
Respiratory and Pulmonary system
|
|
InKemia IUCT group |
IUCT-DS-0263 |
Biodrugs/ Drugs |
Cancer |
Prostate cancer |
1NRP |
Europe |
IUCT-DS-0263
Therapeutic area:
Cancer
|
|
InKemia IUCT group |
DIS-COM-BRA |
Biodrugs/ Drugs |
Analgesia & Pain
Autoimmune & Inflammation |
Inflammation |
1NRP |
|
DIS-COM-BRA
Therapeutic area:
Analgesia & Pain
Autoimmune & Inflammation
|
|
InKemia IUCT group |
IUCT-DS-0423 |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
1NRP |
|
IUCT-DS-0423
Therapeutic area:
Cancer
|
|
InKemia IUCT group |
IUCT-DS-0347 |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
1NRP |
|
IUCT-DS-0347
Therapeutic area:
Cancer
|
|
InKemia IUCT group |
IUCT-DS-0263 |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
1NRP |
|
IUCT-DS-0263
Therapeutic area:
Cancer
|
|
InKemia IUCT group |
IUCT-DS-0086 |
Biodrugs/ Drugs |
Cancer |
Breast cancer |
1NRP |
|
IUCT-DS-0086
Therapeutic area:
Cancer
|
|
InKemia IUCT group |
DIS-COM-COAG |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems |
Anticoagulants |
1NRP |
|
DIS-COM-COAG
Therapeutic area:
Cardiovascular and circulatory systems
|
|
InKemia IUCT group |
DIS-BIO-EPS |
Biodrugs/ Drugs |
Analgesia & Pain
Autoimmune & Inflammation |
Osteoarthritis |
1NRP |
|
DIS-BIO-EPS
Therapeutic area:
Analgesia & Pain
Autoimmune & Inflammation
|
|
InKemia IUCT group |
DIS-BIO-VIR |
Biodrugs/ Drugs |
Infections |
Antivirals |
1NRP |
|
DIS-BIO-VIR
Therapeutic area:
Infections
|
|
InKemia IUCT group |
DIS-BIO-CAN |
Biodrugs/ Drugs |
Cancer |
Antineoplastic |
1NRP |
|
DIS-BIO-CAN
Therapeutic area:
Cancer
|
 |
Institut Quimic de Sarrià (IQS) |
Chondro-implant |
Gene / Cell Therapy |
Cardiovascular and circulatory systems |
Bioactive implant for myocardial regeneration, ventricular support and elliptical shape restoration. Acute Cartilage Injure |
1NRP |
|
Chondro-implant
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Institut Quimic de Sarrià (IQS) |
Cardio-implant |
Gene / Cell Therapy |
Cardiovascular and circulatory systems |
PCL (Polycaprolactone), SAP (self-assembling peptide) bioactive and biomimetic scaffolds for cartilage regeneration. Heart infarct |
1NRP |
|
Cardio-implant
Therapeutic area:
Cardiovascular and circulatory systems
|
 |
Iproteos |
IPR-166 |
Biodrugs/ Drugs |
Central Nervous System |
Cognitive Impairment Associated with Schizophrenia (CIAS) |
2RP |
|
IPR-166
Therapeutic area:
Central Nervous System
|
|
Iproteos |
IPR-179 |
Biodrugs/ Drugs |
Central Nervous System |
Epilepsy |
1NRP |
|
IPR-179
Therapeutic area:
Central Nervous System
|
 |
IRYCIS |
New compound for the treatment of isquemical stroke |
Biodrugs/ Drugs |
Central Nervous System |
Isquemic stroke |
1NRP |
Spain |
New compound for the treatment of isquemical stroke
Therapeutic area:
Central Nervous System
|
 |
Lipopharma Therapeutics |
LP204A1 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Inflammation |
1NRP |
|
LP204A1
Therapeutic area:
Autoimmune & Inflammation
|
|
Lipopharma Therapeutics |
LP561A1 |
Biodrugs/ Drugs |
Cancer |
Glioma and other solid tumours |
4PhII |
|
LP561A1
Therapeutic area:
Cancer
|
|
Lipopharma Therapeutics |
LP226A1 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's Disease |
2RP |
Europe |
LP226A1
Therapeutic area:
Central Nervous System
|
|
Lipopharma Therapeutics |
LP30171 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Metabolic Diseases |
1NRP |
|
LP30171
Therapeutic area:
Metabolic / Endocrinology
|
|
Lipopharma Therapeutics |
LP205A1 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Cardiovascular and Metabolic Diseases |
1NRP |
Europe |
LP205A1
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
|
Lipopharma Therapeutics |
LPA181 |
Biodrugs/ Drugs |
Central Nervous System |
Spinal Cord Injuries |
1NRP |
|
LPA181
Therapeutic area:
Central Nervous System
|
 |
Minoryx |
MIN101 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology |
Adrenoleukodystrophy |
2RP |
|
MIN101
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
|
|
Minoryx |
MIN-102 |
Biodrugs/ Drugs |
Central Nervous System
Metabolic / Endocrinology |
X-linked Adrenoleukodystrophy |
3PhI |
|
MIN-102
Therapeutic area:
Central Nervous System
Metabolic / Endocrinology
|
 |
NATAC |
Retriacyl |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Retinitis Pigmentosa |
5PhIII |
Europe |
Retriacyl
Therapeutic area:
Ophthalmology and optometry
|
 |
Neuron Bio |
NPS0158 |
Biodrugs/ Drugs |
Central Nervous System |
Mild Cognitive Impairment |
1NRP |
Europe |
NPS0158
Therapeutic area:
Central Nervous System
|
|
Neuron Bio |
NPS0163 |
Biodrugs/ Drugs |
Central Nervous System |
Mild Cognitive Impairment |
1NRP |
Europe |
NPS0163
Therapeutic area:
Central Nervous System
|
|
Neuron Bio |
NST0078 |
Biodrugs/ Drugs |
Central Nervous System |
Mild Cognitive Impairment / Epilepsy |
1NRP |
Europe |
NST0078
Therapeutic area:
Central Nervous System
|
|
Neuron Bio |
NST0076 |
Biodrugs/ Drugs |
Central Nervous System |
Mild Cognitive Impairment / Epilepsy |
1NRP |
Europe |
NST0076
Therapeutic area:
Central Nervous System
|
|
Neuron Bio |
NST0037 |
Biodrugs/ Drugs |
Central Nervous System |
Mild Cognitive Impairment / Epilepsy |
2RP |
Europe |
NST0037
Therapeutic area:
Central Nervous System
|
 |
nLife Therapeutics, S.L. |
NLF-PD-1233 |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson Disease |
2RP |
Europe and USA |
NLF-PD-1233
Therapeutic area:
Central Nervous System
|
 |
Oryzon |
ORY-3001 |
Biodrugs/ Drugs |
Others |
Non-oncological disease |
2RP |
|
ORY-3001
Therapeutic area:
Others
|
|
Oryzon |
ORY-1001 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Acute Myeloid Leukaemia, Solid tumors, Other oncohaematology indications |
3PhI |
|
ORY-1001
Therapeutic area:
Blood and Lymphatic systems
Cancer
|
|
Oryzon |
OG-new series in KDM |
Biodrugs/ Drugs |
Cancer
Others |
Solid cancers, Oncohaematology |
1NRP |
|
OG-new series in KDM
Therapeutic area:
Cancer
Others
|
|
Oryzon |
ORY-2001 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease, Multiple Sclerosis, Huntington's disease, other dementias, |
3PhI |
|
ORY-2001
Therapeutic area:
Central Nervous System
|
 |
PaloBiofarma |
PBF-695 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Glaucoma |
2RP |
|
PBF-695
Therapeutic area:
Ophthalmology and optometry
|
|
PaloBiofarma |
PBF-999 |
Biodrugs/ Drugs |
Central Nervous System |
Huntington Disease |
2RP |
|
PBF-999
Therapeutic area:
Central Nervous System
|
|
PaloBiofarma |
PBF-509 |
Biodrugs/ Drugs |
Cancer
Central Nervous System |
Attention-Deficit, Hyperactivity Disorder (ADHD), Lung Cancer |
3PhI |
|
PBF-509
Therapeutic area:
Cancer
Central Nervous System
|
|
PaloBiofarma |
PBF680 |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Asthma |
3PhI |
|
PBF680
Therapeutic area:
Respiratory and Pulmonary system
|
 |
PANGAEA ONCOLOGY |
PB1 |
Biodrugs/ Drugs |
Cancer |
CNS, Neuroderived tumours, Local delivery |
1NRP |
|
PB1
Therapeutic area:
Cancer
|
 |
Pevesa |
PEV pept. 01-02 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Metabolic Syndrome |
2RP |
Europe |
PEV pept. 01-02
Therapeutic area:
Metabolic / Endocrinology
|
 |
PharmaMar |
Lurbinectedin |
Biodrugs/ Drugs |
Cancer |
Platinum-Resistant Ovarian Cancer |
5PhIII |
|
Lurbinectedin
Therapeutic area:
Cancer
|
|
PharmaMar |
Aplidin |
Biodrugs/ Drugs |
Cancer |
Multiple Myeloma |
5PhIII |
|
Aplidin
Therapeutic area:
Cancer
|
|
PharmaMar |
Aplidin |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
T Cell Lymphoma |
4PhII |
|
Aplidin
Therapeutic area:
Blood and Lymphatic systems
Cancer
|
|
PharmaMar |
Aplidin |
Biodrugs/ Drugs |
Cancer |
Multiple Myeloma in combination with bortezomid |
4PhII |
|
Aplidin
Therapeutic area:
Cancer
|
|
PharmaMar |
Lurbinectedin |
Biodrugs/ Drugs |
Cancer |
Combination trials |
3PhI |
|
Lurbinectedin
Therapeutic area:
Cancer
|
|
PharmaMar |
PM184 |
Biodrugs/ Drugs |
Cancer |
Combination trials |
3PhI |
|
PM184
Therapeutic area:
Cancer
|
|
PharmaMar |
Lurbinectedin |
Biodrugs/ Drugs |
Cancer |
Small Cell Lung Cancer |
5PhIII |
|
Lurbinectedin
Therapeutic area:
Cancer
|
|
PharmaMar |
Lurbinectedin |
Biodrugs/ Drugs |
Cancer |
Basket trial |
4PhII |
|
Lurbinectedin
Therapeutic area:
Cancer
|
|
PharmaMar |
PM184 |
Biodrugs/ Drugs |
Cancer |
Advanced Breast cancer |
4PhII |
|
PM184
Therapeutic area:
Cancer
|
|
PharmaMar |
Lurbinectedin |
Biodrugs/ Drugs |
Cancer |
BRCA Associated Breast Cancer |
4PhII |
|
Lurbinectedin
Therapeutic area:
Cancer
|
 |
PRAXIS |
NANOPLATFORMM |
Biodrugs/ Drugs |
Infections |
NANOFORMULATION OF DRUGS FOR RESISTANT INFECTIONS |
1NRP |
|
NANOPLATFORMM
Therapeutic area:
Infections
|
|
PRAXIS |
EPIPROT |
Biodrugs/ Drugs |
Dermatology |
Diabetic Foot |
5PhIII |
|
EPIPROT
Therapeutic area:
Dermatology
|
|
PRAXIS |
NANOENZHIMES |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
SANFILIPPO/FABRY |
1NRP |
|
NANOENZHIMES
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
PRAXIS |
NNE |
Biodrugs/ Drugs |
Dermatology |
Diabetic Foot |
1NRP |
|
NNE
Therapeutic area:
Dermatology
|
|
PRAXIS |
TAT-CF |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
CYSTIC FIBROSIS |
1NRP |
|
TAT-CF
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
PRAXIS |
TERFIQEC |
Gene / Cell Therapy |
Genetic Diseases and Dysmorphic syndromes |
Cystic Fibrosis |
2RP |
|
TERFIQEC
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
PRAXIS |
NANOCANTHER |
Biodrugs/ Drugs |
Cancer |
THERAPY SYSTEMS FOR PANCREATIC CANCER |
1NRP |
|
NANOCANTHER
Therapeutic area:
Cancer
|
|
PRAXIS |
Fibrodress |
Biodrugs/ Drugs |
Central Nervous System |
Dressing for Neuropathic bounds |
2RP |
|
Fibrodress
Therapeutic area:
Central Nervous System
|
|
PRAXIS |
LP561A1 |
Biodrugs/ Drugs |
Cancer |
GLIOMA |
4PhII |
|
LP561A1
Therapeutic area:
Cancer
|
|
PRAXIS |
BIOTCARM |
Biodrugs/ Drugs |
Cancer |
GLIOMA |
4PhII |
|
BIOTCARM
Therapeutic area:
Cancer
|
|
PRAXIS |
PROHEAL |
Biodrugs/ Drugs |
Dermatology |
Bioactive wound dressings (Diabetic / vascular) |
2RP |
|
PROHEAL
Therapeutic area:
Dermatology
|
|
PRAXIS |
Nanoantibiotics |
Gene / Cell Therapy |
Respiratory and Pulmonary system |
Resistent Infections (Cystic Fibrosis) |
1NRP |
|
Nanoantibiotics
Therapeutic area:
Respiratory and Pulmonary system
|
|
PRAXIS |
ANTIAGE |
Biodrugs/ Drugs |
Dermatology |
ANTIAGING DRUGS AND NUTRACEUTICS |
2RP |
|
ANTIAGE
Therapeutic area:
Dermatology
|
|
PRAXIS |
BIOTCATM |
Biodrugs/ Drugs |
Cancer |
Cancer |
1NRP |
|
BIOTCATM
Therapeutic area:
Cancer
|
|
PRAXIS |
OLEA |
Biodrugs/ Drugs |
Dermatology |
ANTIAGING DRUGS AND NUTRACEUTICS |
2RP |
|
OLEA
Therapeutic area:
Dermatology
|
|
PRAXIS |
BERENICE |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
Chagas |
5PhIII |
|
BERENICE
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
PRAXIS |
ALZHEIMER |
Biodrugs/ Drugs |
Central Nervous System |
ALZHEIMER |
1NRP |
|
ALZHEIMER
Therapeutic area:
Central Nervous System
|
|
PRAXIS |
TERARMET |
Biodrugs/ Drugs |
Others |
SANFILIPPO |
1NRP |
|
TERARMET
Therapeutic area:
Others
|
 |
REIG JOFRE |
Bioadhesive topical gel |
Biodrugs/ Drugs |
Dermatology |
Impetigo, skin infections |
5PhIII |
|
Bioadhesive topical gel
Therapeutic area:
Dermatology
|
 |
REIG JOFRE/LABORATORIOS MEDEA |
Topical solution |
Biodrugs/ Drugs |
Dermatology |
Skyn infection |
5PhIII |
|
Topical solution
Therapeutic area:
Dermatology
|
 |
Sanifit |
SNF472 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Cardiovascular disease (dialysis) |
4PhII |
|
SNF472
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
|
Sanifit |
SNF472 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Calciphylaxis (dialysis) |
4PhII |
|
SNF472
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
 |
SOM Biotech |
SOM0226 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology |
All Types of Transthyretin Amyloidosis: Familial Amyloid Polyneuropathy, Familial Amyloid Cardiomyopathy, Senile Systemic Amyloidosis, Ophthalmic and CNS forms. |
5PhIII |
|
SOM0226
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
|
|
SOM Biotech |
SOM3355 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes |
Huntington's disease, Tourette syndrome and Tardive Dyskinesia |
4PhII |
|
SOM3355
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
|
|
SOM Biotech |
SOM1201 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes |
Adrenoleukodystrophy |
4PhII |
|
SOM1201
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
|
|
SOM Biotech |
SOM0777 |
Biodrugs/ Drugs |
Cancer |
Glioblastoma |
1NRP |
|
SOM0777
Therapeutic area:
Cancer
|
|
SOM Biotech |
SOM2201 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders |
Duchenne Muscular Dystrophy |
1NRP |
|
SOM2201
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Musculoskeletal Disorders
|
 |
SPHERIUM BIOMED S.L |
SP15016 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Kidney and Genitourinary system |
Prevention of Acute Kidney Injury in Angioplasty patients receiving high dose contrast agent |
2RP |
|
SP15016
Therapeutic area:
Cardiovascular and circulatory systems
Kidney and Genitourinary system
|
|
SPHERIUM BIOMED S.L |
SP13004 |
Biodrugs/ Drugs |
Cancer
Dermatology
Digestive System |
Prevention and treatment of radiochemotherapy-induced mucositis in head and neck cancer |
4PhII |
|
SP13004
Therapeutic area:
Cancer
Dermatology
Digestive System
|
|
SPHERIUM BIOMED S.L |
SP12006 |
Biodrugs/ Drugs |
Analgesia & Pain
Musculoskeletal Disorders |
Treatment of mild to moderate muscular pain (related to sportive practice DOMS and Temporomandibular Joint Disorder) |
4PhII |
|
SP12006
Therapeutic area:
Analgesia & Pain
Musculoskeletal Disorders
|
|
SPHERIUM BIOMED S.L |
SP14019 |
Biodrugs/ Drugs |
Dermatology |
topical spray of cyclosporine to treat Atopic Dermatitis & Psoriasis |
4PhII |
|
SP14019
Therapeutic area:
Dermatology
|
 |
Stem Center S.L.U. |
GID SVF-1 |
Gene / Cell Therapy |
Others |
Plastic and reconstructive surgery |
6Reg. |
Europe |
GID SVF-1
Therapeutic area:
Others
|
 |
Sylentis |
siRNA |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Ocular Allergy |
2RP |
|
siRNA
Therapeutic area:
Ophthalmology and optometry
|
|
Sylentis |
SYL1001 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Dry Eye Syndrome |
5PhIII |
|
SYL1001
Therapeutic area:
Ophthalmology and optometry
|
|
Sylentis |
Bamosiran/SYL040012 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Ocular Hypertension, Glaucoma |
4PhII |
|
Bamosiran/SYL040012
Therapeutic area:
Ophthalmology and optometry
|
|
Sylentis |
siRNA |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Digestive System |
Crohn's disease and ulcerative colitis |
2RP |
|
siRNA
Therapeutic area:
Autoimmune & Inflammation
Digestive System
|
 |
TERACLON IDF |
T1649 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Psoriasis |
1NRP |
|
T1649
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
|
TERACLON IDF |
V-32-R |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Glaucoma |
2RP |
|
V-32-R
Therapeutic area:
Ophthalmology and optometry
|
|
TERACLON IDF |
V32R |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Diabetic Retinopathy |
2RP |
|
V32R
Therapeutic area:
Ophthalmology and optometry
|
 |
Thrombotargets |
TT-112 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Antifibrinolysis |
1NRP |
|
TT-112
Therapeutic area:
Blood and Lymphatic systems
|
|
Thrombotargets |
TT-173 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemorrhage |
5PhIII |
|
TT-173
Therapeutic area:
Blood and Lymphatic systems
|
 |
VCN Biosciences |
VCN-01 |
Gene / Cell Therapy |
Cancer |
Pancreatic cancer |
3PhI |
Europe |
VCN-01
Therapeutic area:
Cancer
|
|
VCN Biosciences |
VCN-02 |
Gene / Cell Therapy |
Cancer |
Solid Tumors |
1NRP |
|
VCN-02
Therapeutic area:
Cancer
|
 |
VENTER PHARMA |
LacTEST |
Biodrugs/ Drugs |
Digestive System |
Evaluation of hypolactasia |
6Reg. |
|
LacTEST
Therapeutic area:
Digestive System
|
 |
Vivacell Biotechnology Espa |
VCE-003.2 |
Biodrugs/ Drugs |
Central Nervous System |
Huntington Disease |
1NRP |
|
VCE-003.2
Therapeutic area:
Central Nervous System
|
|
Vivacell Biotechnology Espa |
VCE-004.8 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Central Nervous System |
Multiple Sclerosis |
1NRP |
|
VCE-004.8
Therapeutic area:
Autoimmune & Inflammation
Central Nervous System
|
 |
VIVEBIOTECH |
GMP-grade viral vectors |
Gene / Cell Therapy |
Genetic Diseases and Dysmorphic syndromes |
Development of gene therapy products in strict compliance with requirements established under current legislation and in accordance with best practice guidelines in a cleanroom for the production of medicines for Stage I/II clinical trials. |
2RP |
|
GMP-grade viral vectors
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
 |
Vivia Biotech |
Vivia 011 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity, Diabetes |
1NRP |
|
Vivia 011
Therapeutic area:
Metabolic / Endocrinology
|
|
Vivia Biotech |
Vivia 009 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Central Nervous System |
Non Hodgkin Lymphoma, CNS |
2RP |
Europe |
Vivia 009
Therapeutic area:
Blood and Lymphatic systems
Central Nervous System
|
 |
Vytrus Biotech |
PhyPsor |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Psoriasis |
1NRP |
|
PhyPsor
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|